You are viewing an incomplete version of our website. Please click to reload the website as full version.

HER2 antibody (V-Erb-B2 erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/glioblastoma Derived Oncogene Homolog (Avian)) (C-Term)

Details for Product anti-ERBB2 Antibody No. ABIN180481, Supplier: Login to see
Antigen
  • CD340
  • HER-2
  • HER-2/neu
  • HER2
  • MLN 19
  • NEU
  • NGL
  • TKR1
  • Erbb-2
  • Neu
  • c-erbB2
  • c-neu
  • mKIAA3023
Alternatives
anti-Human HER2 antibody for Western Blotting
Epitope
C-Term
117
83
65
56
56
55
51
44
36
33
32
29
22
20
20
20
20
19
19
19
19
19
19
18
18
18
16
14
14
14
13
13
13
12
10
10
9
9
8
8
7
7
7
7
7
7
6
6
6
6
6
6
6
6
6
6
6
6
6
6
5
5
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Reactivity
Human
1182
409
236
25
12
4
3
3
3
3
2
2
1
1
1
Host
Rabbit
957
364
21
19
5
5
Clonality (Clone)
Monoclonal ()
Conjugate
This HER2 antibody is un-conjugated
67
62
52
45
45
41
11
9
9
8
8
8
8
8
8
2
2
1
Application
Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
645
520
328
323
227
197
137
123
93
52
24
21
17
6
6
6
5
5
3
3
2
2
1
1
1
1
Supplier
Login to see
Supplier Product No.
Login to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Immunogen A synthetic cyclic peptide from the antigen's C-terminus.
Clone BV5
Isotype IgG
Specificity Cellular Localization:Membrane.
Characteristics Synonyms: HER-2, NEU, p185erbB2, NGL, c-erbB-2, MNL19, Receptor tyrosine-protein kinase erbB-2,NEU proto-oncogene, Tyrosine kinase-type cell surface receptor HER2
Purification Supernatant
Alternative Name CD340 / ERBB2 / HER2 (ERBB2 Antibody Abstract)
Background HER2/neu (also known as c-erbB-2) is a member of the epidermal growth factor receptor (EGFR) family notable for its role in the pathogenesis of breast cancer and as a target of treatment. It is a cell membrane surface-bound tyrosine kinase normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is a proto-oncogene located at the long arm of human chromosome 17(17q11.2-q12).Synonyms: HER-2, MNL19, NEU, NEU proto-oncogene, NGL, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, c-erbB-2, p185erbB2
Gene ID 2064
UniProt P04626
Pathways RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway
Application Notes Positive Control: Breast carcinoma
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Buffer Buffer pH 7.5, containing BSA as stabilizer and Sodium Azide as preservative.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Storage Comment Store the antibody (undiluted) at 2-8 °C.
Shelf life: one year from despatch.
Expiry Date 12 months
Background publications Jacobs, Gown, Yaziji et al.: "HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement." in: American journal of clinical pathology, Vol. 113, Issue 2, pp. 251-8, 2000 (PubMed).

Gorlick, Huvos, Heller et al.: "Expression of HER2/erbB-2 correlates with survival in osteosarcoma." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 17, Issue 9, pp. 2781-8, 2000 (PubMed).

Keshgegian, Cnaan: "erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody." in: American journal of clinical pathology, Vol. 108, Issue 4, pp. 456-63, 1997 (PubMed).

Wright, Angus, Nicholson et al.: "Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer." in: Cancer research, Vol. 49, Issue 8, pp. 2087-90, 1989 (PubMed).

Wright, Nicholson, Angus et al.: "Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer." in: British journal of cancer, Vol. 65, Issue 1, pp. 118-21, 1992 (PubMed).